FAQ: VolitionRx's Agreement with Werfen for APS Diagnostic Testing
Summary
What is the main purpose of the agreement between VolitionRx and Werfen?
The agreement is a Research License and Exclusive Commercial Option Rights Agreement to assess antiphospholipid syndrome (APS) using Volition’s Nu.Q H3.1 Neutrophil Extracellular Traps (NETs) assay on Werfen’s diagnostic platforms.
Why is this partnership significant for APS patients?
This partnership could improve both decision-making and ongoing patient monitoring for APS, a complex autoimmune disorder affecting around 4 million people, potentially allowing better management of this very complex syndrome.
How does Volition’s Nu.Q NETs test work and what makes it unique?
The Nu.Q NETs assay detects NETs levels in patients and is believed to be the first CE-IVD biomarker being investigated in APS, which could serve as a risk indicator of thrombosis in APS patients.
Who are the key companies and individuals involved in this agreement?
VolitionRx Ltd. (NYSE American: VNRX) and Werfen’s Immunoassay Technology Center are the companies involved, with key individuals including Gael Forterre (Volition’s Chief Commercial Officer) and Marta Palicio (Werfen’s Immunoassay Technology Center Innovation R&D Director).
What progress has already been made with the technology transfer?
Werfen has successfully transferred the Nu.Q NETs assay to their ACL AcuStar platform, and early results in NETs levels detection in APS patients with the Nu.Q test are encouraging.
What are the next steps in this collaboration?
The next steps include further validation and completion of a clinical utility study to determine the potential role of this marker as a risk indicator of thrombosis in APS patients.
How does this agreement fit into Volition’s overall business strategy?
This agreement implements Volition’s strategy to out-license their proprietary Nu.Q NETs test to large worldwide companies to leverage their disease knowledge, product development, regulatory experience, and installed base of proprietary analyzers.
Where can I find more information about VolitionRx and this announcement?
For more information, visit Volition’s website at www.Volition.com or view the full press release at https://ibn.fm/DXJnL. Note that website contents are not incorporated by reference into official documents.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 202383